Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Browse other coverage
Latest from the blog
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
BPC-157 and night sweats: what we know
Night sweats appear in BPC-157 user reports but not in any published study. Here is what the evidence and the likely mechanism actually show.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
GLP-1R G protein bias via ECL3 displacement
A July 2026 Cell Reports study shows N-terminal modifications to GLP-1R agonists shift signalling toward G protein by displacing extracellular loop 3.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
Skin Growths, Sermorelin, and BPC-157/TB500
Community reports link sermorelin and BPC-157/TB-500 use to acanthosis. Here is what the IGF-1 and skin-biology literature actually shows.